The vast majority of good science and excellent ideas do not translate into products . Many good products that have the potential to assist in diagnosis and therapy do not mature into everyday care . This often becomes a source of frustration for innovators, academic institutions, companies both small and large, and investors . The``innovation paradox", wherein excellent ideas and good science fail to reach the bedside, is a major challenge . This study presents the Active Compass model as a way to overcome this obstacle . The model is designed to assist projects at early stages by redirecting and reshaping them in a way that increases their chances of reaching the markets . The model is based on the use of next-generation translational research and on creating differentiators at the early stages of development . The proposed model's implementation by innovators, scientists, technology transfer offices, academic institutions, analysts, and investors can help move forward high-potential projects to improve the quality of life and alleviate the burdens of disease.